Which generation of targeted therapy does Crizotinib belong to?

Crizotinib (Crizotinib) is a first-generation targeted therapy drug. As a pioneering targeted drug for ALK (anaplastic lymphoma kinase) and ROS1-positive non-small cell lung cancer, crizotinib has revolutionized lung cancer treatment in clinical application and has become an important treatment option for patients with ALK-positive lung cancer. Its advent has greatly improved the prognosis of these patients and created a new situation in precision medicine.

As a first-generation drug, crizotinib mainly targets tumor cells driven by ALK and ROS1 gene fusion. By inhibiting the activity of these abnormal kinases, crizotinib effectively blocks the growth signals of tumor cells and inhibits tumor spread and proliferation. This precise strike mechanism allows patients to significantly reduce their tumor burden and improve their quality of life after receiving treatment.

However, with prolonged use, some patients will develop drug resistance, which has prompted the development of more advanced second- and third-generation ALK inhibitors. These subsequent generations of drugs have been improved on the basis of crizotinib and can overcome drug-resistant mutations, improve the penetration of brain metastases, and extend the progression-free survival of patients. Despite this, crizotinib remains the initial treatment of choice for many patients.

In general, crizotinib, as the first-generation targeted therapy drug, is a milestone in the field of lung cancer treatment. It not only opens up the road to precise targeted therapy, but also provides valuable experience for the subsequent development of higher-generation drugs. Although there are drug resistance problems, its clinical value cannot be ignored, and it is still an important treatment option for patients with ALK-positive lung cancer.

Reference materials:https://go.drugbank.com/drugs/DB08865